Derma Sciences (DSCI) 10-Q 6 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 05, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'DERMA SCIENCES, INC.	'
Entity Central Index Key	'0000892160	'
Trading Symbol	'DSCI	'
Amendment Flag	'false	'
Document Type	'10-Q	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'
Document Period End Date	30-Jun-14	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	25,248,398

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$57,089,886	$6,501,586
Short-term investments	31,493,000	15,478,000
Accounts receivable, net	7,860,975	7,332,756
Inventories	17,599,680	16,472,640
Prepaid expenses and other current assets	3,065,618	3,746,753
Total current assets	117,109,159	49,531,735
Long-term investments	7,565,683	7,858,140
Equipment and improvements, net	3,231,956	2,953,469
Identifiable intangible assets, net	14,534,750	14,635,998
Goodwill	13,457,693	13,457,693
Other assets	147,310	139,318
Total Assets	156,046,551	88,576,353
Current Liabilities	'	'
Accounts payable	4,625,433	4,522,508
Accrued expenses and other current liabilities	4,493,913	4,969,225
Total current liabilities	9,119,346	9,491,733
Long-term liabilities	232,977	242,325
Deferred tax liability	1,735,859	1,694,147
Total Liabilities	11,088,182	11,428,205
Contingencies (note 9)	'	'
Stockholders' Equity	'	'
Convertible preferred stock, $.01 par value; shares authorized 1,468,750; issued and outstanding 73,332 at June 30, 2014 and December 31, 2013 (liquidation preference of $3,222,368 at June 30, 2014)	733	733
Common stock, $.01 par value; shares authorized 50,000,000; issued and outstanding 25,236,582 at June 30, 2014 and 17,347,071 at December 31, 2013	252,366	173,471
Additional paid-in capital	226,351,602	140,064,607
Accumulated other comprehensive income	1,481,296	1,080,148
Accumulated deficit	-83,127,628	-64,170,811
Total Stockholders' Equity	144,958,369	77,148,148
Total Liabilities and Stockholders' Equity	$156,046,551	$88,576,353

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Consolidated Balance Sheets [Abstract]	'	'
Convertible preferred stock, par value per share	$0.01	$0.01
Convertible preferred stock, shares authorized	1,468,750	1,468,750
Convertible preferred stock, shares issued	73,332	73,332
Convertible preferred stock, shares outstanding	73,332	73,332
Convertible preferred stock, liquidation preference	$3,222,368	'
Common stock, par value per share	$0.01	$0.01
Common stock, shares authorized	50,000,000	35,000,000
Common stock, shares issued	25,236,582	17,347,071
Common stock, shares outstanding	25,236,582	17,347,071

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Consolidated Statements of Comprehensive Loss [Abstract]	'	'	'	'
Net Sales	$20,916,225	$18,148,061	$40,703,258	$36,937,807
Cost of sales	13,071,408	11,473,900	25,946,117	23,559,181
Gross Profit	7,844,817	6,674,161	14,757,141	13,378,626
Operating Expenses	'	'	'	'
Selling, general and administrative	12,631,590	10,823,370	25,681,143	20,676,455
Research and development	4,365,267	3,242,599	8,548,868	6,235,765
Total operating expenses	16,996,857	14,065,969	34,230,011	26,912,220
Operating loss	-9,152,040	-7,391,808	-19,472,870	-13,533,594
Other (income) expense, net:	-233,050	-16,733	-272,300	72,072
Loss before income taxes	-8,918,990	-7,375,075	-19,200,570	-13,605,666
Income tax benefit	-232,188	-30,402	-243,753	-16,214
Net Loss	-8,686,802	-7,344,673	-18,956,817	-13,589,452
Other Comprehensive Income (Loss)	'	'	'	'
Foreign currency translation adjustment	117,750	-169,419	-84,862	-219,100
Unrealized gain on equity securities, net of taxes	862,685	'	486,010	'
Total other comprehensive income (loss)	980,435	-169,419	401,148	-219,100
Comprehensive Loss	($7,706,367)	($7,514,092)	($18,555,669)	($13,808,552)
Net loss per common share - basic and diluted	($0.34)	($0.43)	($0.79)	($0.81)
Shares used in computing net loss per common share - basic and diluted	25,199,805	17,068,854	23,889,487	16,832,578

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Operating Activities	'	'
Net loss	($18,956,817)	($13,589,452)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of equipment and improvements	450,734	467,400
Amortization of identifiable intangible assets	1,480,998	1,447,327
Provision for bad debts	9,942	14,000
Allowance for sales adjustments	-5,642	-16,805
Provision for inventory obsolescence	65,069	73,781
Deferred rent	-10,142	16,945
Stock-based compensation	3,495,944	2,806,137
Deferred income taxes	-219,514	74,639
Changes in operating assets and liabilities:	'	'
Accounts receivable	-521,797	-349,151
Inventories	-1,333,931	-732,687
Prepaid expenses and other current assets	785,061	83,236
Other assets	25,541	-431
Accounts payable	89,676	871,362
Accrued expenses and other current liabilities	-424,585	30,839
Net cash used in operating activities	-15,069,463	-8,802,860
Investing Activities	'	'
Purchase of investments	-35,000,000	-16,475,000
Proceeds from sale of investments	19,981,000	2,737,000
Purchase of equipment and improvements	-733,436	-282,574
Purchase of intangible assets	-1,250,000	-100,000
Net cash used in investing activities	-17,002,436	-14,120,574
Financing Activities	'	'
Proceeds from the sale of common stock, net of costs	80,616,032	'
Proceeds from exercise of stock options and warrants, net of costs	2,245,782	2,750,549
Payment of withholding taxes related to employee stock compensation	-121,618	-76,446
Net cash provided by financing activities	82,740,196	2,674,103
Effect of exchange rate changes on cash and cash equivalents	-79,997	35,277
Net increase (decrease) in cash and cash equivalents	50,588,300	-20,214,054
Cash and cash equivalents	'	'
Beginning of period	6,501,586	41,616,657
End of period	57,089,886	21,402,603
Supplemental disclosures of cash flow information:	'	'
Issuance of a warrant in connection with a licensing agreement	129,750	'
Cash paid during the year for interest	$5,442	$717

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Organization and Summary of Significant Accounting Policies [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	1	Organization and Summary of Significant Accounting Policies
	Derma Sciences, Inc. and its subsidiaries (the “Company”) is a tissue regeneration company focused on three segments of the wound care marketplace: advanced wound care, traditional wound care and pharmaceutical wound care products. The Company has one drug candidate that initiated its Phase 3 study during the first quarter of 2013. The Company markets its products principally through direct sales representatives in the United States (“U.S.”), Canada and the United Kingdom (“U.K.”), and through independent distributors within other select international markets. The Company's U.S. distribution facilities are located in St. Louis, Missouri and Houston, Texas. The Company utilizes third party distributors for distribution in Canada, Europe and the Far East. The Company has manufacturing facilities in Toronto, Canada and Nantong, China.
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2014, are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. Information included in the consolidated balance sheet as of December 31, 2013 has been derived from the consolidated financial statements and footnotes thereto for the year ended December 31, 2013, included in the Annual Report on Form 10-K previously filed with the Securities and Exchange Commission. For further information refer to the Annual Report on Form 10-K.
	Principles of Consolidation – The consolidated financial statements include the accounts of Derma Sciences, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates – The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on knowledge of current events and actions which may be undertaken in the future, actual results may ultimately differ from these estimates. Estimates and assumptions are required in the determination of sales deductions for trade rebates, sales incentives, discounts and allowances. Significant estimates and assumptions are also required in determining the appropriateness of amortization periods for identifiable intangible assets, the potential impairment of goodwill and the valuation of inventory.
	Revenue Recognition – Sales are recorded when product is shipped or title passes to customers and collectability is reasonably assured. Gross sales are adjusted for cash discounts, returns and allowances, trade rebates, distribution fees (in Canada) and other sales deductions in the same period that the related sales are recorded. Freight costs billed to and reimbursed by customers are recorded as a component of revenue. Freight costs to ship product to customers are recorded as a component of cost of sales.
	Net Loss per Share – Net loss per common share – basic is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Net loss per common share – diluted reflects the potential dilution of earnings by including the effects of the assumed exercise, conversion or issuance of potentially issuable shares of common stock (“potentially dilutive securities”), including those attributable to stock options, warrants, convertible preferred stock and restricted stock units in the weighted average number of common shares outstanding for a period, if dilutive. The effects of the assumed exercise of warrants and stock options are determined using the treasury stock method. Potentially dilutive securities have not been included in the computation of diluted loss per share for the three and six months ended June 30, 2014 and 2013 as the effect would be anti-dilutive.
	Potentially dilutive shares excluded as a result of the effects being anti-dilutive are as follows:
			Three and Six Months Ended June 30,
			2014	2013
	Excluded dilutive shares:
	Convertible preferred stock		73,332	73,332
	Additional stock issuable related to conversion of preferred stock		49,782	73,566
	Restricted share units		744,850	802,800
	Stock options		2,324,554	1,853,805
	Warrants		2,143,584	2,305,593
	Total dilutive shares		5,336,102	5,109,096
	Recently Issued Accounting Pronouncements – In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2014-09,  Revenue from Contracts with Customers , which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

Cash_and_Cash_Equivalents_and_

Cash and Cash Equivalents and Investments	6 Months Ended
	Jun. 30, 2014
Cash and Cash Equivalents and Investments [Abstract]	'
Cash and Cash Equivalents and Investments	'
	2	Cash and Cash Equivalents and Investments
	Cash and Cash Equivalents
	The Company considers cash and cash equivalents as amounts on hand, on deposit in financial institutions and highly liquid investments purchased with an original maturity of three months or less. Money market mutual funds consist of funds deposited into mutual funds investing in U.S. government and non-government obligations. The Company maintains cash and cash equivalents and money market mutual funds with various domestic and foreign financial institutions within the ordinary course of business, which at times may exceed jurisdictional insurance limits.
	Investments in Debt Securities
	Investments in debt securities includes certificates of deposit purchased with an original maturity greater than three months which are deposited in various U.S. financial institutions and are fully insured by the Federal Deposit Insurance Corporation. The Company intends to hold the certificates of deposit to maturity and accordingly these investments are carried at amortized cost. Investments in debt securities with maturities greater than one year from the balance sheet date are classified as a long-term asset.
	Investment in Equity Securities
	In 2013, the Company purchased 2,272,277 shares of Comvita Limited (“Comvita”) common stock for $7,000,000. The equity investment represented 7.3% of Comvita's outstanding shares on the date of purchase. In conjunction with this investment, the Company's chairman and chief executive officer was named to Comvita's board of directors. Comvita will use the proceeds from this investment to purchase additional apiaries and upgrade and expand its Manuka honey processing capabilities. This investment will assist Comvita in its effort to better ensure supply for the Company's medical-grade honey requirements in an environment of growing global demand for Manuka honey.
	The investment in Comvita common stock is classified as an available-for-sale investment carried at fair value, with any unrealized gains and losses associated with the investment included in accumulated other comprehensive income and any dividends received recorded in other income. The investment is classified as a long term asset. As of June 30, 2014, the fair value of the Comvita common stock was $7,565,683 as determined by the quoted market price of the outstanding stock on the New Zealand stock exchange. The cumulative increase in fair value from cost of $565,683, net of taxes of $217,533, has been recorded in accumulated other comprehensive income.
	Cash and cash equivalents and investments at June 30, 2014 and December 31, 2013 consisted of the following:
			30-Jun-14		December 31, 2013
	Cash		$	6,775,752	$	5,265,903
	Money market mutual funds			50,314,134		1,235,683
	Cash and cash equivalents			57,089,886		6,501,586
	Investments in debt securities			31,493,000		16,474,000
	Investment in equity securities			7,565,683		6,862,140
	Total investments			39,058,683		23,336,140
	Total cash and cash equivalents and investments		$	96,148,569	$	29,837,726
	The following table provides fair value information as of June 30, 2014:
					Fair Value Measurements, Using
			Total carrying		Quoted prices		Significant other		Significant
			value as of		in active		observable		unobservable
			30-Jun-14		markets		inputs		inputs
					(Level 1)		(Level 2)		(Level 3)
	Cash and cash equivalents		$	57,089,886	$	57,089,886	$	-	$	-
	Investments in debt securities			31,493,000		31,489,965		-		-
	Investment in equity securities			7,565,683		7,565,683		-		-
	Total investments			39,058,683		39,055,648		-		-
	Total		$	96,148,569	$	96,145,534	$	-	$	-
	Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets. Level 2 inputs are quoted prices for similar assets in active markets or inputs that are observable for the asset, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management's own assumptions used to measure assets at fair value. A financial asset's classification is determined based on the lowest level input that is significant to the fair value measurement.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventories [Abstract]	'
Inventories	'
	3	Inventories
	Inventories are valued at the lower of cost or market determined based on the first in first out method and include the following:
			30-Jun-14		31-Dec-13
	Finished goods		$	12,380,839	$	11,044,746
	Work in process			667,773		1,009,315
	Packaging materials			1,369,982		1,408,521
	Raw materials			3,181,086		3,010,058
	Total inventory		$	17,599,680	$	16,472,640

BioDLogics_LLC_License_Agreeme

BioDLogics, LLC License Agreement	6 Months Ended
	Jun. 30, 2014
BioDLogics, LLC License Agreement [Abstract]	'
BioDLogics, LLC License Agreement	'
	4	BioDLogics, LLC License Agreement
	On January 14, 2014, the Company entered into a license, market development and commercialization agreement (the “Agreement”) with BioDLogics, LLC (“BioD”) relating to BioD's human placental based products (the “Licensed Products”) and intellectual property related thereto.
	Under the Agreement, BioD granted to the Company an exclusive, perpetual, royalty-bearing license to use, offer for sale and sell, the Licensed Products in North America (the “Territory”), including the rights to sublicense solely as provided in the Agreement, for a broad range of dermal applications, (the “Field”). During the term of the Agreement, the Company will be responsible for the sale and marketing of the Licensed Products in the Field throughout the Territory. As part of its commercialization efforts, the Company is required to fund clinical studies up to $2,000,000 in support of the Field pursuant to the Agreement.
	The Company paid BioD an initial license fee of $1,250,000 and granted BioD a warrant to purchase 100,000 shares of the Company's common stock. One quarter (25%) of the warrant was exercisable immediately at a price of $11.81, while the remaining 75% of the warrant becomes exercisable, if at all, upon the achievement of certain milestones. The warrant expires five years from the date of issuance in January 2019 (note 5). The warrant has been valued at $129,750 using the Black-Scholes option pricing model. Total consideration paid to BioD of $1,379,750 has been recorded as an intangible asset and is being amortized to cost of sales over an estimated useful life of seven years. In addition to the initial license fee and warrant, royalties are payable to BioD based upon a sliding scale of the Company's net sales of Licensed Products within the Territory and declining as net sales increase. Royalty rates range from the low double digits and decline to the mid-single digits. The Agreement also requires the Company to make milestone payments to BioD of up to $19,750,000 based upon the achievement of certain development events and annual net sales levels.
	The Agreement may be terminated as follows: (i) upon mutual agreement of the parties; (ii) by BioD if the Company challenges certain BioD patents or trade secrets; (iii) by BioD if the Company fails to meet the annual minimum net sales requirement under the Agreement, unless the Company pays the difference between the amount of royalties that would have been due had the minimum annual net sales for such year been achieved and royalty payments made by the Company with respect to net sales during such year plus any milestone payments payable; or (iv) by either party in the event of a material breach or certain events of bankruptcy.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	5	Stockholders' Equity
	Preferred Stock
	Subsequent to the issuances of the preferred stock, the Company has undertaken a number of common stock offerings that impact the preferred stock conversion ratios. As of June 30, 2014, current Series A and B preferred stockholders holding 73,332 preferred shares are entitled to receive an aggregate of 123,114 shares (49,782 additional shares) of common stock upon conversion of their holdings, as a result of the conversion ratio adjustments. The number of shares issuable upon conversion is subject to further adjustment should the Company in the future undertake one or more offerings of its common stock at less than the prevailing market price. In the six months ended June 30, 2014, the Company issued 1,397 common shares to prior preferred stock holders based on the adjustment of the conversion ratios.
	The 49,782 incremental shares associated with the conversion ratio adjustment will be recorded to common stock at par with the offset to additional paid in capital as all of the convertible preferred stock was issued prior to the November 16, 2000 effective date of certain provisions of Accounting Standards Codification 470 (formerly, EITF 00-27 Application of Issue No. 98-5 to Certain Convertible Instruments).
	Common Stock
	On January 29, 2014, the Company raised $80,616,032 (net of $5,633,968 in commission and other offering expenses) from the sale of 7,500,000 shares of the Company's common stock at $11.50 per share. The Company plans to use the net proceeds from the offering for the continued development of its pharmaceutical product DSC127, for sales force expansion and for general corporate purposes.
	On May 20, 2014, stockholders of the Company approved the proposal to increase the number of authorized shares of common stock from 35,000,000 to 50,000,000. On June 6, 2014, the Company amended its Certificate of Incorporation to reflect the increase in the number of authorized common stock. During the six months ended June 30, 2014, the Company issued 7,889,511 shares of common stock consisting of: 7,500,000 shares in connection with the January 29, 2014 equity offering, 325,621 shares upon the exercise of stock purchase warrants and options for which the Company received $2,245,782; 62,493 shares in connection with the vesting of 71,800 restricted share units, and 1,397 shares in connection with preferred stock conversion ratio adjustments.
	Stock Purchase Warrants
	At June 30, 2014, the Company had warrants outstanding to purchase shares of the Company's common stock consisting of the following:
	Series		Number of Warrants			Exercise Price			Expiration Date
	N			100,000		$	6.25		22-Feb-15
	O			102,734		$	5.5		22-Feb-15
	P			2,187		$	6.25		16-Feb-15
	Q			133,333		$	5.5		22-Feb-15
	R			1,705,330		$	9.9		22-Jun-16
	S			100,000		$	11.81		14-Jan-19
	Total			2,143,584
	During the six months ended June 30, 2014, a total of 261,688 warrants were exercised on a for cash and cashless basis consisting of 128,166 Series O, 127,272 Series R, and 6,250 Series L warrants. A total of 260,111 shares of common stock were issued in connection with the 2014 warrant exercises.
	Equity Based Compensation
	Under the Equity Incentive Plan (the “EIP Plan”) the Company is authorized to issue shares of common stock. On May 20, 2014, stockholders of the Company approved the proposal to increase the number of authorized shares of common stock the Company can issue from 4,500,000 to 6,000,000. The EIP Plan authorizes the Company to grant equity-based and cash-based incentive compensation in the form of stock options, stock appreciation rights, restricted shares, restricted share units, other share-based awards and cash-based awards, for the purpose of providing the Company's employees, non-employee directors and consultants with incentives and rewards for performance. At June 30, 2014, options to purchase 2,324,554 shares and 744,850 restricted share units were issued and outstanding under the EIP Plan and 2,235,035 shares were available for grant.
	Stock Options
	The EIP Plan permits the granting of both incentive and nonqualified stock options to employees and nonqualified stock options to non-employee directors and consultants of the Company. The option exercise price may not be less than the fair market value of the stock on the date of the grant of the option. The duration of each option may not exceed 10 years from the date of grant.
	For the three and six months ended June 30, 2014 and 2013, the fair value of each option award was estimated at the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used were as follows:
			Three Months Ended June 30,						Six Months Ended June 30,
			2014			2013			2014			2013
	Risk-free interest rate			1.97	%		1.16	%		1.79	%		1.22	%
	Volatility factor			61.9	%		70.2	%		63.2	%		70	%
	Dividend yield			0	%		0	%		0	%		0	%
	Expected option life (years)			6.25			6.25			5.89			6.25
	The risk-free rate utilized represents the U.S. treasury yield curve rate for the expected option life at the time of grant. The volatility factor was calculated based on the Company's historical stock price volatility equal to the expected life of the option at the grant date. The dividend yield is 0% since the Company does not anticipate paying dividends in the near future. The simplified expected option life method is used to determine the expected option life for Company employees and directors while the contractual option life period is utilized for consultants.
	Based on the Company's historical experience of options that were forfeited before becoming fully vested, the Company has assumed an annualized forfeiture rate of 1.0% for all options. The Company will record additional expense if the actual forfeiture rate is lower than estimated, and will record a recovery of prior expense if the actual forfeiture rate is higher than estimated.
	A summary of the Company's stock option activity and related information for the six months ended June 30, 2014 is as follows:
			Options			Weighted Average Exercise Price
	Outstanding – January 1, 2014			1,814,233		$	7.67
	Granted			628,661		$	13.04
	Forfeited			(12,662	)	$	12.13
	Exercised			(102,178	)	$	6.95
	Expired			(3,500	)	$	12.28
	Outstanding – June 30, 2014			2,324,554		$	9.12
	Expected to vest – June 30, 2014			2,301,308		$	9.12
	Exercisable at June 30, 2014			1,557,590		$	7.53
	During 2014, the Company granted 443,335 service based options and 185,326 performance based options to Company employees and consultants. The weighted average fair value per share of options granted during the six months ended June 30, 2014 was $7.64.
	During the six months ended June 30, 2014, 102,178 stock options were exercised on a for cash and cashless basis. A total of 65,510 shares of common stock were issued in connection with the 2014 stock option exercises. The intrinsic value of options exercised in 2014 was $467,604.
	During the three and six months ended June 30, 2014 and 2013, stock option compensation expense was recorded as follows:
			Three Months Ended June 30,						Six Months Ended June 30,
			2014			2013			2014			2013
	Cost of sales		$	32,870		$	13,636		$	118,046		$	68,343
	Selling, general and administrative expenses			623,336			627,186			1,836,158			1,135,792
	Research and development			82,385			13,895			103,171			71,655
	Total stock option compensation expense		$	738,591		$	654,717		$	2,057,375		$	1,275,790
	As of June 30, 2014, there was $3,429,722 of unrecognized compensation cost related to nonvested service based awards and $498,503 related to nonvested performance based awards. These costs are expected to be recognized over the options' remaining weighted average vesting period of 2.20 years and 0.50 years for the service and performance based awards, respectively.
	Restricted Share Units
	The Company has issued service, performance and market based restricted share units to employees and directors of the Company. Expense for restricted share awards is amortized on a straight-line basis over the awards' vesting period. The fair value of service and performance awards are determined using the quoted market price of the Company's common stock on the date of grant, while market based performance awards are valued using a binomial/lattice pricing model.
	The following table summarizes the restricted share unit activity for the period:
						Weighted
			Number of Units			Average Fair Value
	Unvested–January 1,2014			720,550		$	9.03
	Granted			101,100			10.05
	Vested			-71,800			13.48
	Forfeited			-5,000			10.74
	Unvested–June 30, 2014			744,850		$	8.82
	In connection with the vesting of restricted share unit awards during the six months ended June 30, 2014, 9,307 common stock shares with a fair value of $121,618 were withheld in satisfaction of employee tax withholding obligations.
	During the three months ended June 30, 2014 and 2013, restricted share unit compensation expense was $715,117 and $661,329, and for the six months ended June 30, 2014 and 2013, restricted share unit compensation expense was $1,390,033 and $1,192,925, respectively, and included in selling, general and administrative expense.
As of June 30, 2014, there was $4,237,494 of unrecognized compensation cost related to unvested restricted share units. These costs are expected to be recognized over the restricted shares units' remaining weighted average vesting period of 1.32 years.
In consideration of prior service, the Company accelerated the vesting of any unvested stock options and the restricted share units scheduled to vest in 2014 of a retiring director and extended the date to exercise vested stock options to 24 months (versus 90 days) from the date of retirement. An additional $48,536 of stock based compensation expense was recognized during the six months ended June 30, 2014 and included in selling, general and administrative expense in connection with the retirement. For the six months ended June 30, 2013, the Company recognized an additional $337,422 of stock based compensation expense associated with a director's retirement and a former director's consulting expenses which were included in selling, general and administrative expense.
Shares Reserved for Future Issuance
At June 30, 2014, the Company had reserved the following shares of common stock for future issuance:
Convertible preferred stock (series A – B)			73,332
Additional stock issuable related to conversion of preferred stock (series A – B)			49,782
Common stock options outstanding			2,324,554
Common stock warrants outstanding			2,143,584
Restricted share units outstanding			744,850
Common stock equivalents available for grant			2,235,035
Total common stock shares reserved			7,571,137

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Income [Abstract]	'
Accumulated Other Comprehensive Income	'
	6	Accumulated Other Comprehensive Income
			The Company's accumulated other comprehensive income as of June 30, 2014 was as follows:
			Unrealized
	Foreign		(Loss)
	Currency		Gain on Equity
	Translation		Securities,
	Adjustments		Net of Taxes		Total
	Balance at January 1, 2014		$	1,218,008		$	(137,860	)	$	1,080,148
	Current period - other comprehensive (loss) gain			(84,862	)		486,010			401,148
	Balance at June 30, 2014		$	1,133,146		$	348,150		$	1,481,296

Operating_Segments

Operating Segments	6 Months Ended
	Jun. 30, 2014
Operating Segments [Abstract]	'
Operating Segments	'
	7	Operating Segments
	The Company operates in three segments: advanced wound care, traditional wound care and pharmaceutical wound care products. They are managed separately as each segment requires different technology, marketing and sales strategies. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. Pharmaceutical wound care products consist of DSC127, a novel, first in class angiotensin peptide for the treatment of a variety of dermal applications.
	Advanced and traditional wound care products are marketed globally to acute care, extended care, home health care, wound and burn care clinics and physician offices. The Company utilizes a broad network of well-established distributors to deploy the majority of its products to end users. A smaller portion of the Company's sales are sold directly to care providers and through retail. The advanced and traditional wound care products are both manufactured internally and sourced from third party suppliers. The majority of marketing expenses are deployed in support of advanced wound care products with traditional wound care products requiring limited support. The Company utilizes direct sales representatives, distributor relationships and contractual relationships with buying groups and wound care service providers to sell its products. Direct sales representatives are used solely in support of advanced wound care sales in the U.S. and the U.K. and for both advanced and traditional wound care products in Canada.
	The pharmaceutical wound care segment is presently limited to the development of DSC127 for diabetic foot ulcers and pre-clinical work on scar prevention.
	Each operating segment is managed at the segment contribution level consisting of gross profit minus direct expense consisting of distribution, marketing, sales, research and development and intangible amortization expenses. Expenses are allocated directly by segment to the extent possible. Expenses common to all three operating segments are allocated consistently using activity based assumptions. The aggregation or allocation of indirect expenses by segment is not practical.
	Operating segment sales, gross profit, segment contribution and other related information for 2014 and 2013 were as follows:
	Three Months Ended June 30, 2014
			Advanced Wound Care			Traditional			Pharmaceutical Wound Care			Other			Total
						Wound Care									Company
	Net sales		$	8,812,685		$	12,103,540		$	-		$	-		$	20,916,225
	Gross profit			4,446,075			3,398,742			-			-			7,844,817
	Direct expense			(7,663,928	)		(1,362,889	)		(4,361,559	)		-			(13,388,376	)
	Segment contribution		$	(3,217,853	)	$	2,035,853		$	(4,361,559	)		-			(5,543,559	)
	Indirect expenses											$	(3,143,243	)		(3,143,243	)
	Net loss														$	(8,686,802	)
	Three Months Ended June 30, 2013
	Net sales		$	7,910,616		$	10,237,445		$	-		$	-		$	18,148,061
	Gross profit			3,938,156			2,736,005			-			-			6,674,161
	Direct expense			(5,200,282	)		(1,284,977	)		(3,269,670	)		-			(9,754,929	)
	Segment contribution		$	(1,262,126	)	$	1,451,028		$	(3,269,670	)		-			(3,080,768	)
	Indirect expenses											$	(4,263,905	)		(4,263,905	)
	Net loss														$	(7,344,673	)
	Six Months Ended June 30, 2014
			Advanced Wound Care			Traditional			Pharmaceutical Wound Care			Other			Total
						Wound Care									Company
	Net sales		$	17,164,748		$	23,538,510		$	-		$	-		$	40,703,258
	Gross profit			8,373,050			6,384,091			-			-			14,757,141
	Direct expense			(15,309,862	)		(2,671,058	)		(8,540,726	)		-			(26,521,646	)
	Segment contribution		$	(6,936,812	)	$	3,713,033		$	(8,540,726	)		-			(11,764,505	)
	Indirect expenses											$	(7,192,312	)		(7,192,312	)
	Net loss														$	(18,956,817	)
	Six Months Ended June 30, 2013
	Net sales		$	15,398,998		$	21,538,809		$	-		$	-		$	36,937,807
	Gross profit			7,567,297			5,811,329			-			-			13,378,626
	Direct expense			(10,423,871	)		(2,487,944	)		(6,285,762	)		-			(19,197,577	)
	Segment contribution		$	(2,856,574	)	$	3,323,385		$	(6,285,762	)		-			(5,818,951	)
	Indirect expenses											$	(7,770,501	)		(7,770,501	)
	Net loss														$	(13,589,452	)
	The following table presents net sales by geographic region.
			Three Months Ended June 30,						Six Months Ended June 30,
			2014			2013			2014			2013
	United States			75	%		80	%		74	%		79	%
	Canada			16	%		11	%		16	%		13	%
	Other			9	%		9	%		10	%		8	%
	For the six months ended June 30, 2014 and 2013, the Company had a major Canadian customer comprising 16% and 13%, respectively, of consolidated net sales. Due to outstanding rebate obligations, the Company was in a net liability position to this customer at June 30, 2014.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	8	Income Taxes
	The following table summarizes the income tax expense and effective tax rate for the three and six months ended June 30, 2014 and 2013:
			Three Months Ended June 30,
				2014			2013
	Current tax benefit		$	(17,093	)	$	(72,832	)
	Deferred tax (benefit) expense			(215,095	)		42,430
	Income tax benefit		$	(232,188	)	$	(30,402	)
	Effective tax rate			2.6	%		0.4	%
			Six Months Ended June 30,
			2014			2013
	Current tax benefit		$	(24,239	)	$	(90,853	)
	Deferred tax (benefit) expense			(219,514	)		74,639
	Income tax benefit		$	(243,753	)	$	(16,214	)
	Effective tax rate			1.3	%		0.1	%
	The income tax benefit for the three and six months ended June 30, 2014 consisted of a U.S. deferred income tax benefit related to a reduction in the Company's U.S. valuation allowance to offset the tax impact of the unrealized gain on equity securities included in accumulated other comprehensive income and a tax benefit from foreign operations. In addition, the U.S. income tax benefit for the three and six months ended June 30, 2014 was reduced by the tax effect of differences in financial reporting and tax treatment of goodwill net of amortization for financial reporting but not for tax purposes of acquired MedEfficiency identified intangible assets.
	The income tax benefit for the three and six months ended June 30, 2013 consisted of a U.S. deferred income tax expense and foreign tax benefit. The U.S. income tax expense for the three and six months ended June 30, 2013 related to tax differences in financial reporting and tax treatment of goodwill net of amortization for financial reporting but not for tax purposes of acquired MedEfficiency identified intangible assets.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2014
Contingencies [Abstract]	'
Contingencies	'
	9	Contingencies
	On occasion, the Company is involved in claims and other legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company's consolidated financial position, results of operations, or liquidity.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policy)	6 Months Ended
	Jun. 30, 2014
Organization and Summary of Significant Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2014, are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. Information included in the consolidated balance sheet as of December 31, 2013 has been derived from the consolidated financial statements and footnotes thereto for the year ended December 31, 2013, included in the Annual Report on Form 10-K previously filed with the Securities and Exchange Commission. For further information refer to the Annual Report on Form 10-K.
Principles of Consolidation	'
	Principles of Consolidation – The consolidated financial statements include the accounts of Derma Sciences, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates – The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on knowledge of current events and actions which may be undertaken in the future, actual results may ultimately differ from these estimates. Estimates and assumptions are required in the determination of sales deductions for trade rebates, sales incentives, discounts and allowances. Significant estimates and assumptions are also required in determining the appropriateness of amortization periods for identifiable intangible assets, the potential impairment of goodwill and the valuation of inventory.
Revenue Recognition	'
	Revenue Recognition – Sales are recorded when product is shipped or title passes to customers and collectability is reasonably assured. Gross sales are adjusted for cash discounts, returns and allowances, trade rebates, distribution fees (in Canada) and other sales deductions in the same period that the related sales are recorded. Freight costs billed to and reimbursed by customers are recorded as a component of revenue. Freight costs to ship product to customers are recorded as a component of cost of sales.
Net Loss per Share	'
	Net Loss per Share – Net loss per common share – basic is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Net loss per common share – diluted reflects the potential dilution of earnings by including the effects of the assumed exercise, conversion or issuance of potentially issuable shares of common stock (“potentially dilutive securities”), including those attributable to stock options, warrants, convertible preferred stock and restricted stock units in the weighted average number of common shares outstanding for a period, if dilutive. The effects of the assumed exercise of warrants and stock options are determined using the treasury stock method. Potentially dilutive securities have not been included in the computation of diluted loss per share for the three and six months ended June 30, 2014 and 2013 as the effect would be anti-dilutive.
	Potentially dilutive shares excluded as a result of the effects being anti-dilutive are as follows:
		Three and Six Months Ended June 30,
		2014	2013
	Excluded dilutive shares:
	Convertible preferred stock	73,332	73,332
	Additional stock issuable related to conversion of preferred stock	49,782	73,566
	Restricted share units	744,850	802,800
	Stock options	2,324,554	1,853,805
	Warrants	2,143,584	2,305,593
	Total dilutive shares	5,336,102	5,109,096
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements – In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2014-09,  Revenue from Contracts with Customers , which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Organization and Summary of Significant Accounting Policies [Abstract]	'
Potentially Dilutive Shares Excluded as Result of Effects Being Anti-dilutive	'
	Potentially dilutive shares excluded as a result of the effects being anti-dilutive are as follows:
		Three and Six Months Ended June 30,
		2014	2013
	Excluded dilutive shares:
	Convertible preferred stock	73,332	73,332
	Additional stock issuable related to conversion of preferred stock	49,782	73,566
	Restricted share units	744,850	802,800
	Stock options	2,324,554	1,853,805
	Warrants	2,143,584	2,305,593
	Total dilutive shares	5,336,102	5,109,096

Cash_and_Cash_Equivalents_and_1

Cash and Cash Equivalents and Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Cash and Cash Equivalents and Investments [Abstract]	'
Schedule of Cash and Cash Equivalents and Investments	'
	Cash and cash equivalents and investments at June 30, 2014 and December 31, 2013 consisted of the following:
		30-Jun-14		December 31, 2013
	Cash	$	6,775,752	$	5,265,903
	Money market mutual funds		50,314,134		1,235,683
	Cash and cash equivalents		57,089,886		6,501,586
	Investments in debt securities		31,493,000		16,474,000
	Investment in equity securities		7,565,683		6,862,140
	Total investments		39,058,683		23,336,140
	Total cash and cash equivalents and investments	$	96,148,569	$	29,837,726
Fair Value of Cash and Cash Equivalents and Investments	'
	The following table provides fair value information as of June 30, 2014:
				Fair Value Measurements, Using
		Total carrying		Quoted prices		Significant other		Significant
		value as of		in active		observable		unobservable
		30-Jun-14		markets		inputs		inputs
				(Level 1)		(Level 2)		(Level 3)
	Cash and cash equivalents	$	57,089,886	$	57,089,886	$	-	$	-
	Investments in debt securities		31,493,000		31,489,965		-		-
	Investment in equity securities		7,565,683		7,565,683		-		-
	Total investments		39,058,683		39,055,648		-		-
	Total	$	96,148,569	$	96,145,534	$	-	$	-

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventories [Abstract]	'
Schedule of Inventories	'
	Inventories are valued at the lower of cost or market determined based on the first in first out method and include the following:
		30-Jun-14		31-Dec-13
	Finished goods	$	12,380,839	$	11,044,746
	Work in process		667,773		1,009,315
	Packaging materials		1,369,982		1,408,521
	Raw materials		3,181,086		3,010,058
	Total inventory	$	17,599,680	$	16,472,640

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity [Abstract]	'
Schedule of Warrants Outstanding	'
	At June 30, 2014, the Company had warrants outstanding to purchase shares of the Company's common stock consisting of the following:
	Series	Number of Warrants			Exercise Price			Expiration Date
	N		100,000		$	6.25		22-Feb-15
	O		102,734		$	5.5		22-Feb-15
	P		2,187		$	6.25		16-Feb-15
	Q		133,333		$	5.5		22-Feb-15
	R		1,705,330		$	9.9		22-Jun-16
	S		100,000		$	11.81		14-Jan-19
	Total		2,143,584
Weighted Average Assumptions Used in Estimation of Fair Value of Option Awards	'
	For the three and six months ended June 30, 2014 and 2013, the fair value of each option award was estimated at the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used were as follows:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	Risk-free interest rate		1.97	%		1.16	%		1.79	%		1.22	%
	Volatility factor		61.9	%		70.2	%		63.2	%		70	%
	Dividend yield		0	%		0	%		0	%		0	%
	Expected option life (years)		6.25			6.25			5.89			6.25
Summary of Stock Option Activity	'
	A summary of the Company's stock option activity and related information for the six months ended June 30, 2014 is as follows:
		Options			Weighted Average Exercise Price
	Outstanding – January 1, 2014		1,814,233		$	7.67
	Granted		628,661		$	13.04
	Forfeited		(12,662	)	$	12.13
	Exercised		(102,178	)	$	6.95
	Expired		(3,500	)	$	12.28
	Outstanding – June 30, 2014		2,324,554		$	9.12
	Expected to vest – June 30, 2014		2,301,308		$	9.12
	Exercisable at June 30, 2014		1,557,590		$	7.53
Allocation of Stock Option Compensation Expense	'
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	Cost of sales	$	32,870		$	13,636		$	118,046		$	68,343
	Selling, general and administrative expenses		623,336			627,186			1,836,158			1,135,792
	Research and development		82,385			13,895			103,171			71,655
	Total stock option compensation expense	$	738,591		$	654,717		$	2,057,375		$	1,275,790
Summary of Restricted Share Unit Activity	'
	The following table summarizes the restricted share unit activity for the period:
					Weighted
		Number of Units			Average Fair Value
	Unvested–January 1,2014		720,550		$	9.03
	Granted		101,100			10.05
	Vested		-71,800			13.48
	Forfeited		-5,000			10.74
	Unvested–June 30, 2014		744,850		$	8.82
Common Stock Shares Reserved for Future Issuance	'
	At June 30, 2014, the Company had reserved the following shares of common stock for future issuance:
	Convertible preferred stock (series A – B)		73,332
	Additional stock issuable related to conversion of preferred stock (series A – B)		49,782
	Common stock options outstanding		2,324,554
	Common stock warrants outstanding		2,143,584
	Restricted share units outstanding		744,850
	Common stock equivalents available for grant		2,235,035
	Total common stock shares reserved		7,571,137

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Income [Abstract]	'
Schedule of Accumulated Other Comprehensive Income	'
			Unrealized
	Foreign		(Loss)
	Currency		Gain on Equity
	Translation		Securities,
	Adjustments		Net of Taxes		Total
	Balance at January 1, 2014	$	1,218,008		$	(137,860	)	$	1,080,148
	Current period - other comprehensive (loss) gain		(84,862	)		486,010			401,148
	Balance at June 30, 2014	$	1,133,146		$	348,150		$	1,481,296

Operating_Segments_Tables

Operating Segments (Tables)	6 Months Ended
	Jun. 30, 2014
Operating Segments [Abstract]	'
Schedule of Operating Segment Sales, Gross Profit, Segment Contribution and Other Related Information	'
	Three Months Ended June 30, 2014
		Advanced Wound Care			Traditional			Pharmaceutical Wound Care			Other			Total
					Wound Care									Company
	Net sales	$	8,812,685		$	12,103,540		$	-		$	-		$	20,916,225
	Gross profit		4,446,075			3,398,742			-			-			7,844,817
	Direct expense		(7,663,928	)		(1,362,889	)		(4,361,559	)		-			(13,388,376	)
	Segment contribution	$	(3,217,853	)	$	2,035,853		$	(4,361,559	)		-			(5,543,559	)
	Indirect expenses										$	(3,143,243	)		(3,143,243	)
	Net loss													$	(8,686,802	)
	Three Months Ended June 30, 2013
	Net sales	$	7,910,616		$	10,237,445		$	-		$	-		$	18,148,061
	Gross profit		3,938,156			2,736,005			-			-			6,674,161
	Direct expense		(5,200,282	)		(1,284,977	)		(3,269,670	)		-			(9,754,929	)
	Segment contribution	$	(1,262,126	)	$	1,451,028		$	(3,269,670	)		-			(3,080,768	)
	Indirect expenses										$	(4,263,905	)		(4,263,905	)
	Net loss													$	(7,344,673	)
	Six Months Ended June 30, 2014
		Advanced Wound Care			Traditional			Pharmaceutical Wound Care			Other			Total
					Wound Care									Company
	Net sales	$	17,164,748		$	23,538,510		$	-		$	-		$	40,703,258
	Gross profit		8,373,050			6,384,091			-			-			14,757,141
	Direct expense		(15,309,862	)		(2,671,058	)		(8,540,726	)		-			(26,521,646	)
	Segment contribution	$	(6,936,812	)	$	3,713,033		$	(8,540,726	)		-			(11,764,505	)
	Indirect expenses										$	(7,192,312	)		(7,192,312	)
	Net loss													$	(18,956,817	)
	Six Months Ended June 30, 2013
	Net sales	$	15,398,998		$	21,538,809		$	-		$	-		$	36,937,807
	Gross profit		7,567,297			5,811,329			-			-			13,378,626
	Direct expense		(10,423,871	)		(2,487,944	)		(6,285,762	)		-			(19,197,577	)
	Segment contribution	$	(2,856,574	)	$	3,323,385		$	(6,285,762	)		-			(5,818,951	)
	Indirect expenses										$	(7,770,501	)		(7,770,501	)
	Net loss													$	(13,589,452	)
Schedule of Net Sales by Geographic Region	'
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	United States		75	%		80	%		74	%		79	%
	Canada		16	%		11	%		16	%		13	%
	Other		9	%		9	%		10	%		8	%

Income_Taxes_Tables

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2014
Income Taxes [Abstract]	'
Income Tax Benefit and Effective Tax Rate	'
		Three Months Ended June 30,
			2014			2013
	Current tax benefit	$	(17,093	)	$	(72,832	)
	Deferred tax (benefit) expense		(215,095	)		42,430
	Income tax benefit	$	(232,188	)	$	(30,402	)
	Effective tax rate		2.6	%		0.4	%
		Six Months Ended June 30,
		2014			2013
	Current tax benefit	$	(24,239	)	$	(90,853	)
	Deferred tax (benefit) expense		(219,514	)		74,639
	Income tax benefit	$	(243,753	)	$	(16,214	)
	Effective tax rate		1.3	%		0.1	%

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies (Narrative) (Details)	6 Months Ended
	Jun. 30, 2014
Organization and Summary of Significant Accounting Policies [Abstract]	'
Number of operating segments	3

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies (Potentially Dilutive Shares Excluded as Result of Effects Being Anti-dilutive) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	5,336,102	5,109,096	5,336,102	5,109,096
Convertible preferred stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	73,332	73,332	73,332	73,332
Additional stock issuable related to conversion of preferred stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	49,782	73,566	49,782	73,566
Restricted share units [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	744,850	802,800	744,850	802,800
Warrants [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	2,143,584	2,305,593	2,143,584	2,305,593
Stock options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	2,324,554	1,853,805	2,324,554	1,853,805

Cash_and_Cash_Equivalents_and_2

Cash and Cash Equivalents and Investments (Narrative) (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Cash and Cash Equivalents and Investments [Abstract]	'	'
Equity securities	'	2,272,277
Ownership percentage	'	7.30%
Payments to acquire equity securities	'	$7,000,000
Fair value of equity investment	7,565,683	6,862,140
Unrealized gain recorded in accumulated other comprehensive income	565,683	'
Amount of taxes on unrealized gain on available-for-sale investment	$217,533	'

Cash_and_Cash_Equivalents_and_3

Cash and Cash Equivalents and Investments (Schedule of Cash and Cash Equivalents and Investments) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Cash and Cash Equivalents and Investments [Abstract]	'	'	'	'
Cash	$6,775,752	$5,265,903	'	'
Money market mutual funds	50,314,134	1,235,683	'	'
Cash and cash equivalents	57,089,886	6,501,586	21,402,603	41,616,657
Investments in debt securities	31,493,000	16,474,000	'	'
Investments in equity securities	7,565,683	6,862,140	'	'
Total Investments	39,058,683	23,336,140	'	'
Total cash and cash equivalents and investments	$96,148,569	$29,837,726	'	'

Cash_and_Cash_Equivalents_and_4

Cash and Cash Equivalents and Investments (Fair Value of Cash and Cash Equivalents and Investments) (Details) (USD $)	Jun. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	$57,089,886
Investments	39,058,683
Total	96,148,569
Quoted prices in active markets (Level 1) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	57,089,886
Investments	39,055,648
Total	96,145,534
Significant other observable inputs (Level 2) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	'
Investments	'
Total	'
Significant unobservable inputs (Level 3) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	'
Investments	'
Total	'
Debt Securities [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Investments	31,493,000
Debt Securities [Member] | Quoted prices in active markets (Level 1) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Investments	31,489,965
Debt Securities [Member] | Significant other observable inputs (Level 2) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Investments	'
Debt Securities [Member] | Significant unobservable inputs (Level 3) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Investments	'
Equity Securities [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Investments	7,565,683
Equity Securities [Member] | Quoted prices in active markets (Level 1) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Investments	7,565,683
Equity Securities [Member] | Significant other observable inputs (Level 2) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Investments	'
Equity Securities [Member] | Significant unobservable inputs (Level 3) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Investments	'

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventories [Abstract]	'	'
Finished goods	$12,380,839	$11,044,746
Work in process	667,773	1,009,315
Packaging materials	1,369,982	1,408,521
Raw materials	3,181,086	3,010,058
Total inventory	$17,599,680	$16,472,640

BioDLogics_LLC_License_Agreeme1

BioDLogics, LLC License Agreement (Details) (Licensing Agreements [Member], USD $)	6 Months Ended
	Jun. 30, 2014
Finite-Lived Intangible Assets [Line Items]	'
Commitment to fund clinical studies	$2,000,000
License fee	1,250,000
Shares called by warrant	100,000
Exercise price of warrant issued	11.81
Expiration period	'5 years
Fair value of warrants	129,750
Consideration paid for agreement	1,379,750
Estimated useful life	'7 years
Maximum milestone payments	$19,750,000
Immediately [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Vesting rate	25.00%
Milestones [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Vesting rate	75.00%

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Stockholders' Equity [Abstract]	'	'	'
Convertible preferred stock, shares outstanding	73,332	'	73,332
Number of common stock shares issuable for preferred stock	123,114	'	'
Additional shares issuable	49,782	'	'
Conversion of preferred stock, shares issued	1,397	'	'
Proceeds from the sale of common stock, net of costs	$80,616,032	'	'
Issuance costs	5,633,968	'	'
Number of shares sold	7,500,000	'	'
Common stock, price per share	$11.50	'	'
Number of common shares authorized	50,000,000	'	35,000,000
Shares issued during the period	7,889,511	'	'
Amount received upon the exercise of stock purchase warrants and options	2,245,782	'	'
Shares of common stock issued in connection with the vesting of restricted common stock	62,493	'	'
Shares of restricted common stock vested	71,800	'	'
Shares of common stock issued upon the exercise of stock purchase warrants and options	325,621	'	'
Shares issued for options	65,510	'	'
Intrinsic value of options exercised	467,604	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares authorized	6,000,000	'	4,500,000
Shares available for grant	2,235,035	'	'
Granted	628,661	'	'
Weighted average fair value per share of options granted	$7.64	'	'
Stock options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expiration period	'10 years	'	'
Restricted share units [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Unrecognized compensation cost	4,237,494	'	'
Remaining weighted average vesting period	'1 year 3 months 25 days	'	'
Shares withheld in satisfaction of employee tax withholding obligations	9,307	'	'
Fair value of shares withheld in satisfaction of employee tax withholding obligations	121,618	'	'
Service based options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Granted	443,335	'	'
Unrecognized compensation cost	3,429,722	'	'
Remaining weighted average vesting period	'2 years 2 months 12 days	'	'
Performance based options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Granted	185,326	'	'
Unrecognized compensation cost	$498,503	'	'
Remaining weighted average vesting period	'6 months	'	'

Stockholders_Equity_Schedule_o

Stockholders' Equity (Schedule of Warrants Outstanding) (Details)	6 Months Ended
	Jun. 30, 2014
Class of Warrant or Right [Line Items]	'
Number of Warrants	2,143,584
Warrants exercised	261,688
Warrants exercised, shares issued	260,111
L [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants exercised	6,250
N [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	100,000
Exercise Price	6.25
Expiration Date	22-Feb-15
O [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	102,734
Exercise Price	5.5
Expiration Date	22-Feb-15
Warrants exercised	128,166
P [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	2,187
Exercise Price	6.25
Expiration Date	16-Feb-15
Q [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	133,333
Exercise Price	5.5
Expiration Date	22-Feb-15
R [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	1,705,330
Exercise Price	9.9
Expiration Date	22-Jun-16
Warrants exercised	127,272
S [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	100,000
Exercise Price	11.81
Expiration Date	14-Jan-19

Stockholders_Equity_Weighted_A

Stockholders' Equity (Weighted Average Assumptions Used in Estimation of Fair Value of Option Awards) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stockholders' Equity [Abstract]	'	'	'	'
Risk free interest rate	1.97%	1.16%	1.79%	1.22%
Volatility factor	61.90%	70.20%	63.20%	70.00%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected option life (years)	'6 years 3 months	'6 years 3 months	'5 years 10 months 21 days	'6 years 3 months
Forfeiture rate	1.00%	1.00%	1.00%	1.00%

Stockholders_Equity_Summary_of

Stockholders' Equity (Summary of Stock Option Activity) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Number of Shares	'
Outstanding - beginning balance	1,814,233
Granted	628,661
Forfeited	-12,662
Exercised	-102,178
Expired	-3,500
Outstanding - ending balance	2,324,554
Expected to vest	2,301,308
Exercisable	1,557,590
Weighted Average Exercise Price Per Share	'
Outstanding - beginning balance	$7.67
Granted	$13.04
Forfeited	$12.13
Exercised	$6.95
Expired	$12.28
Outstanding - ending balance	$9.12
Expected to vest	$9.12
Exercisable	$7.53

Stockholders_Equity_Allocation

Stockholders' Equity (Allocation of Stock Option Compensation Expense) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock options [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock based compensation expense	$738,591	$654,717	$2,057,375	$1,275,790
Stock options [Member] | Cost of sales [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock based compensation expense	32,870	13,636	118,046	68,343
Stock options [Member] | Selling, general and administrative expenses [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock based compensation expense	623,336	627,186	1,836,158	1,135,792
Stock options [Member] | Research and development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock based compensation expense	82,385	13,895	103,171	71,655
Restricted share units [Member] | Selling, general and administrative expenses [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock based compensation expense	715,117	661,329	1,390,033	1,192,925
Additional compensation expense due to accelerated vesting	'	'	$48,536	$337,422

Stockholders_Equity_Summary_of1

Stockholders' Equity (Summary of Restricted Share Unit Activity) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Number of Shares	'
Unvested beginning balance	720,550
Granted	101,100
Vested	-71,800
Cancelled	-5,000
Unvested ending balance	744,850
Weighted Average Fair Value	'
Unvested beginning balance	$9.03
Granted	$10.05
Vested	$13.48
Cancelled	$10.74
Unvested ending balance	$8.82

Stockholders_Equity_Common_Sto

Stockholders' Equity (Common Stock Shares Reserved for Future Issuance) (Details)	Jun. 30, 2014
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	7,571,137
Convertible preferred shares (series A - B) [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	73,332
Additional stock issuable related to conversion of preferred stock [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	49,782
Common stock options outstanding [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	2,324,554
Common stock warrants outstanding [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	2,143,584
Restricted share units outstanding [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	744,850
Common stock equivalents available for grant [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	2,235,035

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	'	'	$1,080,148	'
Current period - other comprehensive (loss) gain	980,435	-169,419	401,148	-219,100
Ending balance	1,481,296	'	1,481,296	'
Foreign Currency Translation Adjustments [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	'	'	1,218,008	'
Current period - other comprehensive (loss) gain	'	'	-84,862	'
Ending balance	1,133,146	'	1,133,146	'
Unrealized (Loss) Gain on Equity Securities, Net of Tax [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	'	'	-137,860	'
Current period - other comprehensive (loss) gain	'	'	486,010	'
Ending balance	$348,150	'	$348,150	'

Operating_Segments_Narrative_D

Operating Segments (Narrative) (Details) (Net sales [Member], Customer [Member])	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Net sales [Member] | Customer [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration percentage	16.00%	13.00%

Operating_Segments_Schedule_of

Operating Segments (Schedule of Operating Segment Sales, Gross Profit, Segment Contribution and Other Related Information) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$20,916,225	$18,148,061	$40,703,258	$36,937,807
Gross profit	7,844,817	6,674,161	14,757,141	13,378,626
Direct expense	-13,388,376	-9,754,929	-26,521,646	-19,197,577
Segment contribution	-5,543,559	-3,080,768	-11,764,505	-5,818,951
Indirect expenses	-3,143,243	-4,263,905	-7,192,312	-7,770,501
Net Loss	-8,686,802	-7,344,673	-18,956,817	-13,589,452
Advanced Wound Care [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	8,812,685	7,910,616	17,164,748	15,398,998
Gross profit	4,446,075	3,938,156	8,373,050	7,567,297
Direct expense	-7,663,928	-5,200,282	-15,309,862	-10,423,871
Segment contribution	-3,217,853	-1,262,126	-6,936,812	-2,856,574
Traditional Wound Care [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	12,103,540	10,237,445	23,538,510	21,538,809
Gross profit	3,398,742	2,736,005	6,384,091	5,811,329
Direct expense	-1,362,889	-1,284,977	-2,671,058	-2,487,944
Segment contribution	2,035,853	1,451,028	3,713,033	3,323,385
Pharmaceutical Wound Care [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	'	'	'	'
Gross profit	'	'	'	'
Direct expense	-4,361,559	-3,269,670	-8,540,726	-6,285,762
Segment contribution	-4,361,559	-3,269,670	-8,540,726	-6,285,762
Other [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	'	'	'	'
Gross profit	'	'	'	'
Direct expense	'	'	'	'
Segment contribution	'	'	'	'
Indirect expenses	($3,143,243)	($4,263,905)	($7,192,312)	($7,770,501)

Operating_Segments_Schedule_of1

Operating Segments (Schedule of Net Sales by Geographic Region) (Details) (Net sales [Member], Geographic Concentration Risk [Member])	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Unites States [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Concentration percentage	75.00%	80.00%	74.00%	79.00%
Canada [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Concentration percentage	16.00%	11.00%	16.00%	13.00%
Other [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Concentration percentage	9.00%	9.00%	10.00%	8.00%

Income_Taxes_Schedule_of_Incom

Income Taxes (Schedule of Income Tax Rate Reconciliation) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Abstract]	'	'	'	'
Current tax benefit	($17,093)	($72,832)	($24,239)	($90,853)
Deferred tax (benefit) expense	-215,095	42,430	-219,514	74,639
Income tax benefit	($232,188)	($30,402)	($243,753)	($16,214)
Effective tax rate	2.60%	0.40%	1.30%	0.10%